News

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...
The FTSE 100 began Friday’s session on a positive note, gaining 23 points, reaching 9,124, as investors paid attention to ...
Tan’s venture capital firm, based in San Francisco, has made significant investments in Chinese tech companies, including Semiconductor Manufacturing International Corp (SMIC), China's largest chip ...
Detailed price information for Arbutus Biopharma Corp (ABUS-Q) from The Globe and Mail including charting and trades.
Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...
Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to ...
George Tidmarsh takes over temporarily at CBER following Vinay Prasad’s abrupt departure; Replimmune trial leaders protest ...
Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...
BioNTech reaffirmed its fiscal year 2025 guidance of 1.7 billion-2.2 billion euros compared to the consensus of 2.05 billion ...
Live Updates Live Coverage Has Ended Monday Wrap-up 4:26 pm The Vanguard S&P 500 ETF closed at 580.14 Monday, up 1.5% — almost an exact mirror of Friday’s 1.6% decline. ViaSat Goes to the Moon 1:21 pm ...
BioNTech (BNTX) recently reported significant improvements in its financial performance, with quarterly sales nearly doubling compared to the previous year and a substantial reduction in net losses.
“In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by ...